MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'biotherapeutics'. Sat, 03 Sep 2011 03:02:20 +0100 http://www.medworm.com/index.php?rid=3636023&cid=t_204027_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F9hbKmLSytOc%2F Welcome back, everyone. We hope the weekend was pleasant and refreshing. Now, of course, the routine returns as meetings and deadlines beckon. As we ease in with a mandatory cup of stimulation, here are a few items to help you along. Have a good day and stay in touch… Grifols To Pay $3.4B For Talecris (Bloomberg News) Roche’s Avastin Improved Survival In Ovarian Cancer (Reuters) Merck Strikes Wastewater Deal With Pa. Town (The Reporter) Bristol-Myers’ Melanoma Drug Improves Survival (Bloomberg News) A Look At AstraZeneca’s Plant In China (The Telegraph) Former Wyeth Employees Mourn Plant Closing (The Rockland Journal News) Novartis MS Pill Faces Safety Concerns (Reuters) Erbitux Fails To Stop Early-Stage Colon Cancer (Bloomberg News) Drugmakers Spend Billions On Fre... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3636023 Mon, 07 Jun 2010 11:44:08 +0100 3636023 http://www.medworm.com/index.php?rid=3335570&cid=t_204027_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FJjQGsGxC9zw%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Archimedes Pharma hired Jeff Buchalter as ceo and president. Most recently, he was ceo at Enzon Pharmaceuticals, which is in the process of revamping its strategy under pressure from Carl Icahn and Dellacamera Capital. ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3335570 Fri, 05 Mar 2010 12:40:16 +0100 3335570 http://www.medworm.com/index.php?rid=3244051&cid=t_204027_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FrQeHVwb4YpE%2F And so, another week will soon draw to a close. Our plans for the weekend? Snowballs fights with the short people may be in order, if the weather forecasts are accurate. What about you? Perhaps it will be time to catch up on some reading or take in a flick. Whatever you fancy, we hope you have a good time. Meanwhile, here are a few things to help you through the day. Enjoy, everyone… AstraZeneca Still Waiting For Upside To MedImmune Deal (Bizjournals) Glaxo To Close R&D Site In Italy (Bloomberg News) Vertex Loss Grows With Costs (Reuters) FDA Wants More Info On Protalix Gaucher Drug (PharmaTimes) snow pic courtesy of katmere flickr creative commons (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3244051 Fri, 05 Feb 2010 12:49:12 +0100 3244051 http://www.medworm.com/index.php?rid=2177559&cid=t_204027_131_f&fid=34989&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FGeneticsHealth%2F%7E3%2Fw_HkpoNhkVs%2F For the first time, the US Food and Drug Administration approved the release of a drug made from genetically engineered animals, boosting confidence in the science of gene manipulation. The drug ATryn (GTC Biotherapeutics) was approved on February 6 for the prevention of blood clotting events in patients with hereditary antithrombin (AT) deficiency. ATryn is produced using milk from goats that have been altered to produce extra antithrombin, a natural blood thinner. Hereditary antithrombin deficiency is a genetic condition where the person suffers from serious and recurrent blood clotting, and making them at very high risk for blood clots, organ damage or death. Over 200,000 people in the United States, Canada and Europe are affected by the disease. The FDA’s approval will certainly h... Genetics and Health blogs http://www.medworm.com/rss/comments.php?id=2177559 Wed, 11 Feb 2009 03:54:00 +0100 2177559 http://www.medworm.com/index.php?rid=1830139&cid=t_204027_77_f&fid=37259&url=http%3A%2F%2Fwww.horizonpress.com%2Fblogger%2F2008%2F09%2Ffrom-probiotics-to-therapeutic-drugs.html The human intestine harbours an immense collection of microbes which have co-evolved with us. Recent studies indicate that the gut microbes regulate energy harvest from the diet and participate in the peripheral body metabolism. Gut microbial dysbiosis severely affects many body functions, including a complex interplay of gut-brain interactions, now under intense study. Most probiotic strains belong to the genus Lactobacillus. The promising results of a first generation of probiotic microbes indicate a promising future for coming generations of probiotics. Antibiotic-associated, travellers' and pediatric diarrhea have been most studied, and more recently, inflammatory bowel disease and irritable bowel syndrome. Future probiotics may contain mixes of strains with complementary characteristi... Microbiology Blog: The weblog for microbiologists. blogs http://www.medworm.com/rss/comments.php?id=1830139 Fri, 26 Sep 2008 12:29:00 +0100 1830139 http://www.medworm.com/index.php?rid=957421&cid=t_204027_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F171085099%2F How do you make a small, but persistent biotech with an intellectual property claim go away? Maybe the answer is to pay for a non-exclusive license to use its technology. In this instance, Protiva Biotherapeutics, which is immersed in the hot field of RNAi, will receive an unspecified, one-time payment from Merck, with the potential for milestones and royalties, depending on the progress of various drug candidates. In exchange, Protiva agreed to drop all litigation against Sirna Therapeutics, which Merck bought last year for $1.1 billion. This is key - the deal also includes lifting a preliminary injunction granted last March preventing Sirna from product development using RNAi technology specified in a 2005 strategic alliance agreement with Protiva. In granting the injunction, California ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=957421 Wed, 17 Oct 2007 11:12:34 +0100 957421 http://www.medworm.com/index.php?rid=923807&cid=t_204027_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F164662485%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Wolters Kluwer Health names Cathy Betz as vp, government affairs; Amira Pharmaceuticals named Hari Kumar chief business officer; Pfizer hired Tanya Clemons as vp and chief talent officer; Mylan appointed Greg Sheldon as global chief information officer; Mylan also named Dave Lillback as sr vp and global head of HR; Mylan taps Brian Byala as sr vp and treasurer; Glaxo names Roy Anderson a non-executive director and board member; Kendle named Ken Hintze vp, global cli... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=923807 Wed, 03 Oct 2007 11:38:18 +0100 923807